GSK Providing Refunds for 340B Overcharges During Q1 2020

GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

Drug manufacturer GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

GSK posted a public notice about the repayments on the U.S. Health Resources and Services Administration web site this

Read More »

HRSA Says at Least Three Hospitals Have Lost 340B Eligibility So Far Due to COVID-19 Patient Mix Changes

St. Elizabeth Healthcare in Ft. Thomas, Ky., is one of three hospitals known to have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. More are expected to lose eligibility soon.

The U.S. Health Resources and Services Administration (HRSA) said yesterday it knows of three hospitals that have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. There could

Read More »

Democratic Senator’s Illness Stalls Action on Drug Pricing Indefinitely

Sen. Ben Ray Lujan's (D-N.M.) recent stroke and absence makes it even less likely that Congress will pass Democratic drug pricing legislation any time soon.

Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.

Lujan’s chief of staff

Read More »

Second Major 340B Stakeholder Says Congress May Need to Stop Drug Makers’ Contract Pharmacy Actions

NACHC is the second major 340B covered entity group in recent days to say publicly that Congress might need to resolve the impasse over 340B contract pharmacy.

The National Association of Community Health Centers (NACHC) told Republican members of Congress last week that “congressional action may be the only solution” to drug makers’ “aggressive actions to limit patients’ access to affordable medications at contract pharmacies.”

NACHC’s

Read More »

Apexus Picks Ohio Health System Pharmacy Exec Michelle Wiest For Influential 340B Position

Apexus announced yesterday that it has hired Michelle Wiest, most recently vice president of pharmacy services at UC Health in Cincinnati, to be its senior vice president of 340B policy and compliance.

Michelle Wiest, most recently vice president of pharmacy services at UC Health in Cincinnati, is Apexus’s new senior vice president of 340B policy and compliance.

Apexus announced Wiest’s hiring yesterday. The company said Wiest will oversee its education programming, compliance

Read More »

Despite Initial Optimism, Rural Hospitals Won’t Benefit from 340B Pricing on BMS’s Myeloma Drugs

Rural and free-standing cancer hospitals will not get access to voluntary 340B pricing on Bristol Myers Squibb’s expensive myeloma drugs Revlimid, Pomalyst, and Thalomid under a policy change the company announced last month.

Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.

Earlier

Read More »

Spanberger and Johnson Lining up an Hour of Pro-340B Accolades on U.S. House Floor Next Tuesday

U.S. Reps. Abigail Spanberger (D-Va.) and Dusty Johnson (R-S.D.) are are organizing an hour of end-of-the-day floor speeches by House members lauding the 340B program this Tuesday.

340B covered entity allies in the U.S. House are booking an hour of floor speeches by members lauding the drug discount program next week Tuesday after all legislative business is finished.

Reps. Abigail Spanberger (D-Va.) and Dusty Johnson (R-S.D.) are

Read More »

11 out of 15 Top-Selling Drugs in U.S. Are Subject to 340B Pricing Restrictions, Analysis Shows

Eleven of the 15 top-selling brand drugs in the United States are now subject to manufacturer-imposed 340B pricing restrictions, including eight in the past 90 days, an analysis by health sector communications consulting firm Real Chemistry found. (Note: Sales figures in the chart are in billions of dollars.)

Eleven of the 15 top-selling brand drugs in the United States are now subject to manufacturer-imposed 340B pricing restrictions, including eight in the past 90 days, a new analysis shows.

Real Chemistry, a health sector communications consulting firm, published

Read More »

Kalderos Hires Veteran Health Care Tech Company Leader Brent Dover to be its New CEO

Kalderos today announced the appointment of Brent Dover as CEO. He succeeds company founder Jeremy Docken, who will remain on the board and who's new title is chief strategy officer.

Drug industry technology company Kalderos, which has struggled to launch its 340B Pay service to let drug companies provide 340B pricing as a post-purchase rebate instead of as an up-front discount, has a new chief executive officer.

The company announced

Read More »

News Alert: At 340B Conference, Feds Laud 340B Providers, Criticize Drug Makers Embroiled in Contract Pharmacy Fight

U.S Assistant Surgeon General Krista Pedley (left) and OPA Acting Director Michelle Herzog told health care providers attending the 340B Coalition winter conference they back them in the 340B contract pharmacy fight.

340B program federal administrators told health care providers attending the 340B Coalition winter conference in San Diego today that they are behind them in the battle with drug manufacturers over accessing 340B pricing in the contract pharmacy setting.

The U.S.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live